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Interpreting cost-effectiveness in 
dialysis: can the most expensive 
be more expensive?
PA McFarlane1
In this issue, Tonelli et al. describe the cost-effectiveness of 
arteriovenous fistulae (AVF) screening, and conclude that such a 
program represents “good value for money.” Here, I examine the 
robustness of this conclusion by considering traditional definitions of 
acceptable cost-effectiveness and more pragmatic definitions, which 
include consideration of the maximum amount that society would be 
willing to pay for hemodialysis.
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In this issue, Tonelli and colleagues1 from 
Alberta, Canada, attempt to identify 
whether screening of arteriovenous fi stu-
lae (AVF) represents what they describe 
as “good value for money.” Th e concept of 
‘bang for the buck’ underlies many health-
economic analyses. Typically, we consider 
this concept in the following context: ‘Th is 
new intervention will improve patient 
outcomes but will cost more as well. Is the 
extra benefi t worth at least as much as the 
extra cost?’ Th is common application of 
the ‘bang for the buck’ approach may not 
be in keeping with a more fundamental 
approach to health economics, which is to 
use a fi xed set of resources (money, staff , 
consumables, and so on) in the manner 
that produces the best patient outcomes. 
Those working in dialysis programs 
should be aware that in-center hemodi-
alysis is oft en held up as the benchmark 
maximum that society is willing to pay 
for a chronic life-saving intervention. 
With that in mind, let’s consider whether 
the work of Tonelli et al.1 produces “good 
value for money” for dialysis programs by 
both economic approaches.
An example of a traditional approach 
to determining value for money is anemia 
management. Targeting a higher than 
usual hemoglobin level may cost more 
(because of greater use of erythropoietin 
and iron) but is expected to improve qual-
ity of life. Is the incremental improvement 
in quality of life worth the extra costs of 
anemia therapy? Previous work by Tonelli 
et al. suggests that it is not.2 Th e incre-
mental cost-effectiveness ratio (ICER) 
is commonly used to answer such ques-
tions. Th e ICER is calculated by division 
of the incremental cost by the incremental 
eff ectiveness (ICER =∆C
—
  /∆E
—
  , where ∆C
—
   is 
the diff erence in mean costs and ∆E
—
   is the 
diff erence in mean eff ectiveness). Tonelli 
et al.2 suggested that raising hemoglobin 
from 9.5–10.5 g per dl to 11.0–12.0 g per 
dl cost US$55 295 per quality-adjusted 
life-year gained. Increasing hemoglobin 
further to the 12.0–12.5 g per dl range 
was associated with an ICER of $613 015 
per quality-adjusted life-year. Tonelli et 
al.2 concluded that raising hemoglobin 
to the 11.0–12.0 g per dl range was cost-
eff ective, but higher targets were not. Of 
course, before we can accept or reject a 
new intervention, we need to know the 
maximum amount that the payer would be 
willing to spend for the additional benefi t.3 
In our anemia example, what is the maxi-
mum that we are willing to pay to increase 
quality-adjusted survival? In other fi elds of 
medicine, health economists oft en point 
to the cost of dialysis as a possible maxi-
mum that we would be willing to spend 
to improve survival — a strangely circular 
argument for health economists working 
in nephrology. Other work has suggested 
that the maximum willingness-to-pay 
value for a quality-adjusted life-year is 
between $60 000 and $160 000.4,5 By these 
standards, Tonelli and colleagues’ conclu-
sions about anemia therapy seem sound. In 
their current study, Tonelli et al.1 suggest 
that it costs between $8 000 and $10 000 
to avoid one AVF failure, and they con-
clude that this “may represent good value 
for money.” Unlike in the anemia exam-
ple, where empiric work had suggested a 
possible maximum willingness to pay to 
improve quality of life, no previous work 
has suggested how much we are willing to 
spend to save a fi stula. Should we believe 
Tonelli and colleagues’ conclusions about 
AVF screening? One solution may be to 
perform additional research to quantify 
our willingness to pay in this area. Alterna-
tively, we can look to a broader economic 
view of dialysis to provide answers.
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A broader view of health economics 
is guided by three principles: scarcity 
(we never have enough resources to do 
all the things that we would like), choice 
(given scarcity, we must choose which 
things we will do), and opportunity costs 
(when choosing to use resources in one 
way, we forgo the benefi t of using them 
in alternate ways).6 Just how scarce are 
dialysis resources? Would it be permis-
sible for the costs of dialysis to rise fur-
ther? After adjustment for inflation, it 
would appear that the per-patient costs 
of in-center hemodialysis have fallen over 
time, from about $100 000 per patient-
year in the early 1990s to about $60 000 
now.7 However, any potential savings have 
been erased by the fact that the prevalent 
in-center hemodialysis population has 
more than doubled in that time period.8 
Although we may have been willing to pay 
as much as $100 000 per patient for a year 
of dialysis in 1990, it is unlikely that we are 
willing to pay that much now. Given the 
anecdotal diffi  culties in securing adequate 
ongoing funding for dialysis (not to men-
tion new funding for dialysis expansion) 
that have been seen in many jurisdictions, 
one could argue that the costs of dialysis 
may already be higher than what society is 
willing to pay for this service. To be sure, 
only a small percentage of the world’s 
population has ready access to dialysis. If 
this is the case, then we will indeed have 
diffi  culty interpreting ICERs.
Returning to the article in this issue, 
Tonelli et al.1 would be correct that AVF 
screening is cost-eff ective if we had evi-
dence that it would be acceptable for the 
costs of dialysis to rise by the suggested 
amount. Th is could come in the form of 
agreements from payers to provide extra 
funding, or through research suggesting 
that there were a societal willingness to 
allow the costs of dialysis to rise. I would 
suggest that we lack empiric or even anec-
dotal evidence that this is the case. Alter-
natively, we could consider this or other 
interventions in dialysis to be cost-eff ec-
tive under two other conditions: fi rst, if 
the new intervention were to directly lead 
to cost savings in other areas that were 
equal to or greater than its incremental 
cost; second, if an existing intervention 
were stopped, and the ensuing cost sav-
ings were used to pay for the new inter-
vention. However, if an intervention is 
cost-eff ective by these criteria, it must also 
be achievable within the scarcity limits of 
non-monetary items (for example, within 
achievable staffi  ng or equipment levels).
Using these criteria, it is difficult to 
support Tonelli and colleagues’ conclu-
sion that AVF screening is “good value 
for money.”1 An ICER of $8 000 per AVF 
saved may be reasonable, but no evidence 
is presented that programs would be able 
to aff ord to do mass access screening. To 
be fair, most (if not all) previous cost-
effectiveness studies in hemodialysis 
would also fail to justify their conclusions 
using these criteria. I would suggest that 
until we have evidence supporting an 
increasing willingness to pay for dialysis, 
ICERs will be an insuffi  cient measure. 
Without additional funding, all health-
economic studies in this area should be 
interpreted from a cost–benefi t stand-
point (where both costs and benefits 
are measured in monetary units, and 
incremental costs are off set by benefi ts 
that save money), or from a standpoint 
where the new intervention will displace 
some existing activity in order to free up 
necessary resources. Th e ICER cannot 
trump practical implementation issues. 
Tonelli et al. hint at this by commenting 
that although performing angiography 
produces similar cost-eff ectiveness ratios 
when AVF blood fl ow falls below thresh-
olds of 500 versus 750 ml per minute, the 
500 ml per minute strategy is preferable, 
because it results in fewer people being 
sent to angiography.
Interpreting cost-eff ectiveness studies 
has oft en been diffi  cult, as we do not have 
established maximum willingness-to-pay 
values for many ICERs. Th e current study 
by Tonelli et al.1 is an excellent example 
of this difficulty. I would suggest that 
interpreting cost-eff ectiveness studies is 
even more diffi  cult when the suggested 
criteria are applied. However, it is the 
responsibility of everyone in the dialysis 
fi eld to respect the pragmatic issues that 
arise when working within what is widely 
recognized as the most expensive chronic 
health-care intervention. Th ese interpre-
tive cautions highlight rather than detract 
from the value of economic analyses such 
as this study by Tonelli et al., and they 
highlight the importance of subjecting 
new dialysis interventions to the scrutiny 
of a well-designed economic analysis.
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